AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (192)	8/5/1997 12:12:00 PM
From: Biomaven	of 298

John, While I don't know too much about MS, I believe it is possible to serially track active brain lesions using MRI. If this tracking shows a significant improvement for the group on Myloral, I don't see why this wouldn't be accepted as evidence for the drug's efficacy. Further, while I agree that you can't in general dredge through your data looking for sub-groups where the drug might have shown efficacy, isn't it different where there are a small number of pre-identified sub-groups? This is particularly true where, as is the case here, the earlier trials pointed to a difference in efficacy among the groups. The other way of looking at this of course is not in terms of FDA approval for Myloral, but rather for some validation of the technology at all. I'm not personally in the stock at all (I was short for a while before the Myloral trial results, but then chickened out and covered when the stock showed strength before the results were announced - sigh.) Clearly they are not going to be able to raise more money without some better results, so the question is whether they can come up with something positive before the money runs out. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next